Cargando…

GC/MS analysis of hypoxic volatile metabolic markers in the MDA-MB-231 breast cancer cell line

Hypoxia in disease describes persistent low oxygen conditions, observed in a range of pathologies, including cancer. In the discovery of biomarkers in biological models, pathophysiological traits present a source of translatable metabolic products for the diagnosis of disease in humans. Part of the...

Descripción completa

Detalles Bibliográficos
Autores principales: Issitt, Theo, Reilly, Matthew, Sweeney, Sean T., Brackenbury, William J., Redeker, Kelly R.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Frontiers Media S.A. 2023
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10210155/
https://www.ncbi.nlm.nih.gov/pubmed/37251079
http://dx.doi.org/10.3389/fmolb.2023.1178269
_version_ 1785047007701762048
author Issitt, Theo
Reilly, Matthew
Sweeney, Sean T.
Brackenbury, William J.
Redeker, Kelly R.
author_facet Issitt, Theo
Reilly, Matthew
Sweeney, Sean T.
Brackenbury, William J.
Redeker, Kelly R.
author_sort Issitt, Theo
collection PubMed
description Hypoxia in disease describes persistent low oxygen conditions, observed in a range of pathologies, including cancer. In the discovery of biomarkers in biological models, pathophysiological traits present a source of translatable metabolic products for the diagnosis of disease in humans. Part of the metabolome is represented by its volatile, gaseous fraction; the volatilome. Human volatile profiles, such as those found in breath, are able to diagnose disease, however accurate volatile biomarker discovery is required to target reliable biomarkers to develop new diagnostic tools. Using custom chambers to control oxygen levels and facilitate headspace sampling, the MDA-MB-231 breast cancer cell line was exposed to hypoxia (1% oxygen) for 24 h. The maintenance of hypoxic conditions in the system was successfully validated over this time period. Targeted and untargeted gas chromatography mass spectrometry approaches revealed four significantly altered volatile organic compounds when compared to control cells. Three compounds were actively consumed by cells: methyl chloride, acetone and n-Hexane. Cells under hypoxia also produced significant amounts of styrene. This work presents a novel methodology for identification of volatile metabolisms under controlled gas conditions with novel observations of volatile metabolisms by breast cancer cells.
format Online
Article
Text
id pubmed-10210155
institution National Center for Biotechnology Information
language English
publishDate 2023
publisher Frontiers Media S.A.
record_format MEDLINE/PubMed
spelling pubmed-102101552023-05-26 GC/MS analysis of hypoxic volatile metabolic markers in the MDA-MB-231 breast cancer cell line Issitt, Theo Reilly, Matthew Sweeney, Sean T. Brackenbury, William J. Redeker, Kelly R. Front Mol Biosci Molecular Biosciences Hypoxia in disease describes persistent low oxygen conditions, observed in a range of pathologies, including cancer. In the discovery of biomarkers in biological models, pathophysiological traits present a source of translatable metabolic products for the diagnosis of disease in humans. Part of the metabolome is represented by its volatile, gaseous fraction; the volatilome. Human volatile profiles, such as those found in breath, are able to diagnose disease, however accurate volatile biomarker discovery is required to target reliable biomarkers to develop new diagnostic tools. Using custom chambers to control oxygen levels and facilitate headspace sampling, the MDA-MB-231 breast cancer cell line was exposed to hypoxia (1% oxygen) for 24 h. The maintenance of hypoxic conditions in the system was successfully validated over this time period. Targeted and untargeted gas chromatography mass spectrometry approaches revealed four significantly altered volatile organic compounds when compared to control cells. Three compounds were actively consumed by cells: methyl chloride, acetone and n-Hexane. Cells under hypoxia also produced significant amounts of styrene. This work presents a novel methodology for identification of volatile metabolisms under controlled gas conditions with novel observations of volatile metabolisms by breast cancer cells. Frontiers Media S.A. 2023-05-11 /pmc/articles/PMC10210155/ /pubmed/37251079 http://dx.doi.org/10.3389/fmolb.2023.1178269 Text en Copyright © 2023 Issitt, Reilly, Sweeney, Brackenbury and Redeker. https://creativecommons.org/licenses/by/4.0/This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.
spellingShingle Molecular Biosciences
Issitt, Theo
Reilly, Matthew
Sweeney, Sean T.
Brackenbury, William J.
Redeker, Kelly R.
GC/MS analysis of hypoxic volatile metabolic markers in the MDA-MB-231 breast cancer cell line
title GC/MS analysis of hypoxic volatile metabolic markers in the MDA-MB-231 breast cancer cell line
title_full GC/MS analysis of hypoxic volatile metabolic markers in the MDA-MB-231 breast cancer cell line
title_fullStr GC/MS analysis of hypoxic volatile metabolic markers in the MDA-MB-231 breast cancer cell line
title_full_unstemmed GC/MS analysis of hypoxic volatile metabolic markers in the MDA-MB-231 breast cancer cell line
title_short GC/MS analysis of hypoxic volatile metabolic markers in the MDA-MB-231 breast cancer cell line
title_sort gc/ms analysis of hypoxic volatile metabolic markers in the mda-mb-231 breast cancer cell line
topic Molecular Biosciences
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10210155/
https://www.ncbi.nlm.nih.gov/pubmed/37251079
http://dx.doi.org/10.3389/fmolb.2023.1178269
work_keys_str_mv AT issitttheo gcmsanalysisofhypoxicvolatilemetabolicmarkersinthemdamb231breastcancercellline
AT reillymatthew gcmsanalysisofhypoxicvolatilemetabolicmarkersinthemdamb231breastcancercellline
AT sweeneyseant gcmsanalysisofhypoxicvolatilemetabolicmarkersinthemdamb231breastcancercellline
AT brackenburywilliamj gcmsanalysisofhypoxicvolatilemetabolicmarkersinthemdamb231breastcancercellline
AT redekerkellyr gcmsanalysisofhypoxicvolatilemetabolicmarkersinthemdamb231breastcancercellline